Vimalanand Prabhu, PhD, Merck, Lansdale, PA, discusses the retrospective, multicenter chart review study, Endometrial Cancer Health Outcomes (ECHO). ECHO looked at real-world outcomes in adult women with MSI-high or dMMR advanced/inoperable endometrial cancer, who had progressed after prior systemic therapy. The majority of these patients received second-line immunotherapy with pembrolizumab and achieved a good prognosis, leading to this regimen becoming standard of care. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.
Vimalanand Prabhu is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and shareholder of Merck & Co., Inc., Kenilworth, NJ, USA.